Comparative Pharmacology
Head-to-head clinical analysis: EXOSURF NEONATAL versus INFASURF PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXOSURF NEONATAL versus INFASURF PRESERVATIVE FREE.
EXOSURF NEONATAL vs INFASURF PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exosurf Neonatal is a synthetic pulmonary surfactant containing dipalmitoylphosphatidylcholine (DPPC), cetyl alcohol, and tyloxapol. It reduces surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse and improving lung compliance and gas exchange.
Infasurf (calfactant) is a natural bovine lung extract containing phospholipids (primarily dipalmitoylphosphatidylcholine, DPPC) and surfactant-associated proteins B and C. It reduces alveolar surface tension, preventing end-expiratory collapse and stabilizing alveoli, thereby improving lung compliance and gas exchange.
Not applicable; Exosurf Neonatal is an endotracheal surfactant preparation indicated only for neonatal respiratory distress syndrome. No adult dosing exists.
Not applicable; Infasurf Preservative Free is an intratracheal suspension indicated only for neonatal respiratory distress syndrome (RDS).
None Documented
None Documented
Not defined as terminal elimination half-life due to local pulmonary action. Clinical effect persists for 12–24 hours after a single dose, with surfactant pool turnover occurring over days.
Terminal half-life in preterm infants: 10-17 hours; clearance correlates with lung maturation and surfactant recycling.
Primarily cleared from lungs via macrophage uptake and catabolism; minimal systemic absorption, thus negligible renal or biliary excretion (<1%). Exogenous surfactant components are recycled and re-secreted by type II pneumocytes.
Primarily cleared by alveolar macrophages and lung surfactant turnover; minimal renal or biliary excretion (<1%).
Category C
Category C
Pulmonary Surfactant
Pulmonary Surfactant